英文字典中文字典51ZiDian.com

中文字典辞典英文字典 a b c d e f g h i j k l m n o p q r s t u v w x y z

precentor

XDict

n. 领唱人

PyDict

领唱人

WordNet (r) 3.0 (2006) (WordNet)

precentor
n 1: the musical director of a choir [synonym: {choirmaster},
{precentor}, {cantor}]

The Collaborative International Dictionary of English v.0.48 (gcide)

Precentor \Pre*cen"tor\, n. [L. praecentor, fr. praecinere to
sing before; prae before canere to sing. See {Chant}.]
A leader of a choir; a directing singer. Specifically:
(a) The leader of the choir in a cathedral; -- called also
the {chanter} or master of the choir. --Hook.
(b) The leader of the congregational singing in Scottish and
other churches.
[1913 Webster]

请选择你想看的字典辞典：

单词	字典	翻译
precentor	查看　precentor　在百度字典中的解释	百度英翻中〔查看〕
precentor	查看　precentor　在Google字典中的解释	Google英翻中〔查看〕
precentor	查看　precentor　在Yahoo字典中的解释	Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!

中文字典英文字典工具:

选择颜色:

<style type="text/css">#word104_1 br {display:none;}</style>
<form id="word104_1" method="post" action="http://pt.goldgoldprice.com/index.php" target="_blank">
<div style="width: 140px;border:1px solid #000;background-color:#ffffff;padding: 0px 0px;margin: 0px 0px;align:center;text-align:center;overflow:hidden;"><div id="xcolor1_1" style="font-size:12px;color:#183a00;line-height:16px;font-family: arial; font-weight:bold;background:#94abf0;padding: 3px 1px;text-align:center;"><a href="http://pt.goldgoldprice.com/" alt="英文字典中文字典" title="英文字典中文字典" id="word_name104_1" style="color:#000000;font-size:14px;text-decoration:none;line-height:16px;font-family: arial;" >英文字典中文字典</a></div><table width=100% style='align:center;text-align:left;font-size:12px;background-color:#ffffff;color:#333333;'>
<tr><td style="text-align:center;border:0"><input type=hidden name="word104_hi" value="1">输入中英文单字</td></tr><tr><td style="text-align:center;border:0"><input type="text" name="word104_input" value="" size=10 style="background-color:#ffffff;color:#000;text-decoration:none;font-family: arial;rial;border:1px solid #999;padding:1px!important;"></td></tr><tr style='line-height: 26px;'><td style="text-align:center;border:0"><input type=submit style="background-color:#ccc;color:#000;border:0 none;cursor:pointer;" value="查询字典"></td></tr></table></div>
</form>

英文字典中文字典相关资料:

Biolexis
Biolexis will bring three anti-obesity drugs into the clinic in 2025 Over the long-term, Biolexis seeks to broaden its portfolio to target broader longevity-focused therapies addressing heart disease, diabetes, and potentially dementia
Pipeline – Biolexis
Along with his colleague Dr David Bearss, Hari founded Biolexis Therapeutics in 2021 and developed the groundbreaking MolecuLernTM, a technology that enables rapid discovery and development of novel clinical candidate agents for a variety of therapeutic applications
Biolexis Therapeutics Unlocks a New Frontier in GLP-1 Receptor . . .
LEHI, Utah, March 14, 2025 PRNewswire — Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of the cryo-electron microscopy (cryoEM) structure of BLX-7006, its first-in-class oral small-molecule GLP-1 receptor agonist
Biolexis Therapeutics Announces Positive Results from Expanded Diet . . .
LEHI, Utah, Dec 9, 2024 PRNewswire — Biolexis Therapeutics, a leading metabolic drug discovery company focused on improving the lives of patients with chronic metabolic conditions, including obesity, diabetes, and related diseases, today announced the successful completion of an expanded diet–induced obesity (DIO) trial for its candidate
Biolexis Therapeutics Completes Promising Pre-Clinical Studies on Novel . . .
Lehi, UT – October 29, 2024 – Biolexis Therapeutics, a pioneering biopharmaceutical company focused on developing next-generation weight loss treatments, today announced the successful completion of recent pre-clinical studies for its innovative AMPK agonists The studies highlight the potential of Biolexis’ two isoform-specific AMPK
Biolexis Secures $10 Million in Series A . . . - Biolexis Therapeutics
Biolexis, Inc , a clinical stage AI-driven drug discovery company, announced today the successful closure of a $10 million Series A funding round The investment was led by Clarke Capital, a prominent institutional investor and alternative investment firm
About – Biolexis
Along with his colleague Dr David Bearss, Hari founded Biolexis Therapeutics in 2021 and developed the groundbreaking MolecuLernTM, a technology that enables rapid discovery and development of novel clinical candidate agents for a variety of therapeutic applications
Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs . . .
LEHI, Utah, June 12, 2025 PRNewswire — Biolexis Therapeutics, Inc (www biolexistx com), a clinical-stage therapeutics company pioneering next-generation treatments for metabolic and muscle-wasting diseases, today announced the initiation of Phase I clinical trials for its lead GLP-1 and AMPK small molecule programs These trials, scheduled
Biolexis Unveils Promising Data with an Oral Weight Loss Drug: BLX-7006 . . .
Lehi, UT – September 12, 2024 – Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the remarkable preclinical results of its oral small molecule GLP-1 agonist, BLX-7006
Longevity – Biolexis
Biolexis has the ability to rapidly create novel compounds by leveraging a unique AI-driven discovery engine “As we continue to research, develop, and implement innovative methods to address critical unmet medical needs, we believe our work targeting GLP-1 and AMPK will lead to expanded treatment options not only for obesity and diabetes

中文字典-英文字典 2005-2009